DelveInsight’s ‘Primary Sclerosing Cholangitis Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline Primary Sclerosing Cholangitis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Primary Sclerosing Cholangitis pipeline domain.
Key Takeaways from the Primary Sclerosing Cholangitis Pipeline Report
Primary Sclerosing Cholangitis Overview
Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extrahepatic bile ducts. The condition may lead to cirrhosis of the liver with portal hypertension and end-stage liver disease (ESLD). The main symptoms of primary sclerosing cholangitis (PSC) are feeling tired or weak and having itchy skin.
Other symptoms may include losing weight without trying, poor appetite, fever, and pain in the abdomen. The cause of PSC is not known. A diagnosis of primary sclerosing cholangitis is made based upon a thorough clinical evaluation, a detailed patient history, identification of characteristic findings, and a variety of specialized tests.
Diagnosis is done by cholangiography (magnetic resonance cholangiopancreatography [MRCP] or endoscopic retrograde cholangiopathy [ERCP]). Treatments for primary sclerosing cholangitis focus on managing complications and monitoring liver damage. Endoscopic surgery to remove blockages and enlarge narrowed bile ducts may be of benefit to help prevent liver deterioration in certain cases. Lost vitamins should be replaced when required to prevent complications related to these deficiencies.
Request for a sample report to know more about the Primary Sclerosing Cholangitis treatment algorithm and diagnosis.
Primary Sclerosing Cholangitis Pipeline Analysis: Drug Profile
GS-9674: Gilead Sciences
GS-9674 (Cilofexor) is an orally active, small molecule based nonsteroidal FXR agonist. The drug is in Phase III clinical studies for the treatment of Primary sclerosing cholangitis.
Discover more about the emerging Primary Sclerosing Cholangitis drugs @ Primary Sclerosing Cholangitis Treatment Drugs
Primary Sclerosing Cholangitis Key Companies
Primary Sclerosing Cholangitis Pipeline Therapies
Primary Sclerosing Cholangitis Pipeline Therapeutics Assessment
Scope of the Primary Sclerosing Cholangitis Pipeline Report
Find out more about the Primary Sclerosing Cholangitis treatment options in development @ Primary Sclerosing Cholangitis Clinical Trials
Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Other Trending Reports:
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Contact Us
Kritika Rehani
[email protected]
+1(919)321-6187
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/